In December 2025, CMS announced the Medicare GLP-1 Bridge demonstration, a short-term program that will allow eligible Medicare beneficiaries to access GLP-1 obesity medications at a $50/month co-pay starting July 2026 , using a centralized processor to manage PA, claims adjudication, and payment ( [18] )
In the preclinical literature it is described across six complementary axes: angiogenesis via VEGFR2/eNOS/NO, regulation of FAK-paxillin signalling, protection of the endothelium and the gastric-intestinal mucosa, modulation of the brain-gut axis with the NO pathway, tendon maturation with fibroblast proliferation, and cytoprotection as a common denominator
10.1016/j.phymed.2019.152949 168 ZhanQ.ZhaoJ.LiuL.WangB.HuiJ.LinQ.et al (2023)
These advantages have allowed DSNPs to grow in both numbers and enrollment
Timothy Wilson, Dr
What You Can Do Now If you are currently taking a GLP-1 medication for an approved indication, continue treatment as prescribed and discuss any behavioral or mood changes with your physician at your next appointment
)
